Inmune Stock Today


USD 8.63  0.46  5.63%   

Market Performance
0 of 100
Odds Of Distress
Less than 18
Inmune Bio is trading at 8.63 as of the 27th of June 2022, a 5.63% increase since the beginning of the trading day. The stock's open price was 8.17. Inmune Bio has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Inmune Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of July 2020 and ending today, the 27th of June 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
4th of February 2019
Health Care
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 17.84 M outstanding shares of which 1.25 M shares are currently shorted by private and institutional investors with about 9.78 trading days to cover. More on Inmune Bio

Moving together with Inmune Bio

0.72BCTXBriaCell Therapeutics Financial Report 5th of July 2022 PairCorr

Inmune Bio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Inmune Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Inmune Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Inmune Bio has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 181 K. Net Loss for the year was (30.34 M) with profit before overhead, payroll, taxes, and interest of 181 K.
Inmune Bio currently holds about 74.81 M in cash with (28.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.19.
Inmune Bio has a frail financial position based on the latest SEC disclosures
Roughly 35.0% of the company shares are held by company insiders
Latest headline from INmune Bio USPTO Issues Patent Covering Use of XPro for Treatment of CNS Diseases - Form 8-K -
Fama & French Classification
Average Analyst Recommendation
Analysts covering Inmune Bio report their recommendations after researching Inmune Bio's financial statements, talking to executives and customers, or listening in on Inmune Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Inmune Bio. The Inmune consensus assessment is calculated by taking the average forecast from all of the analysts covering Inmune Bio.
Strong Buy2 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Inmune Bio based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Inmune Bio financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares14.1 M16.1 M
Fairly Down
Slightly volatile
Weighted Average Shares Diluted14.1 M16.1 M
Fairly Down
Slightly volatile
Total Assets107.8 M99.9 M
Significantly Up
Slightly volatile
Total Liabilities21.3 M19.7 M
Significantly Up
Slightly volatile
Current Assets89.1 M82.6 M
Significantly Up
Slightly volatile
Current Liabilities4.7 M4.4 M
Significantly Up
Slightly volatile
Total Debt16.4 M15.2 M
Significantly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Asset Turnover0.00180.0018
Slightly Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Inmune Bio's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Inmune Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Inmune Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inmune Bio's financial leverage. It provides some insight into what part of Inmune Bio's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Inmune Bio's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Inmune Bio deploys its capital and how much of that capital is borrowed.
Inmune Bio cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 15.23 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Inmune Bio has a current ratio of 18.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Inmune Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Inmune Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Inmune Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Inmune to invest in growth at high rates of return. When we think about Inmune Bio's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(29.25 Million)Share
Inmune Bio (INMB) is traded on NASDAQ Exchange in USA. It is located in David Moss, 225 NE Mizner Blvd, Suite 640, Boca Raton, FL 33432, United States and employs 10 people. Inmune Bio is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 145.78 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Inmune Bio's market, we take the total number of its shares issued and multiply it by Inmune Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Inmune Bio conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 17.84 M outstanding shares of which 1.25 M shares are currently shorted by private and institutional investors with about 9.78 trading days to cover. Inmune Bio currently holds about 74.81 M in cash with (28.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.19.
Check Inmune Bio Probability Of Bankruptcy
Inmune Bio secures a total of 17.84 Million outstanding shares. Inmune Bio secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Inmune Ownership Details

Inmune Stock Price Odds Analysis

What are Inmune Bio's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Inmune Bio jumping above the current price in 90 days from now is about 6.42%. The Inmune Bio probability density function shows the probability of Inmune Bio stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.7177. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Inmune Bio will likely underperform. Additionally, the company has an alpha of 0.4015, implying that it can generate a 0.4 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 8.63HorizonTargetOdds Above 8.63
93.53%90 days
Based on a normal probability distribution, the odds of Inmune Bio to move above the current price in 90 days from now is about 6.42 (This Inmune Bio probability density function shows the probability of Inmune Stock to fall within a particular range of prices over 90 days) .

Inmune Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Inmune Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inmune Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inmune Bio's value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares553.6 K4.7 M
Morgan StanleyCommon Shares300.5 K2.5 M
Citadel Advisors LlcCall Options28.9 K243 K
Citadel Advisors LlcPut Options24.7 K208 K
View Inmune Bio Diagnostics

Inmune Bio Historical Income Statement

Inmune Bio Income Statement is one of the three primary financial statements used for reporting Inmune's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Inmune Bio revenue and expense. Inmune Bio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Inmune Bio Operating Expenses is projected to increase significantly based on the last few years of reporting. The past year's Operating Expenses was at 29.33 Million. The current year Research and Development Expense is expected to grow to about 22.2 M, whereas Consolidated Income is forecasted to decline to (31.1 M). View More Fundamentals

Inmune Stock Against Markets

Picking the right benchmark for Inmune Bio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Inmune Bio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Inmune Bio is critical whether you are bullish or bearish towards Inmune Bio at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inmune Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Manager Now


Portfolio Manager

State of the art Portfolio Manager to monitor and improve performance of your invested capital
All  Next Launch Module

Investing Inmune Bio

You need to understand the risk of investing before taking a position in Inmune Bio. The danger of trading Inmune Bio is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Inmune Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Inmune Bio. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Inmune Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Risk vs Return Analysis. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Global Correlations
Find global opportunities by holding instruments from different markets
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
146.6 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.